Related Experiment Video
Updated: May 18, 2026
06:12
Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram
Published on: March 13, 2018
[Towards more efficient clinical trials for multiple system atrophy in Japan]
1Department of Neurology, The University of Tokyo Hospital, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|October 6, 2012
Summary
Multiple system atrophy (MSA) is a rare neurodegenerative disease. Research is advancing to identify genetic links and develop better diagnostic tools and treatments for MSA patients.
Area of Science:
- Neurodegenerative diseases
- Genetics
- Clinical trial design
Context:
- Multiple system atrophy (MSA) presents with autonomic dysfunction, parkinsonism, and cerebellar/pyramidal signs.
- While typically sporadic, familial cases suggest a genetic predisposition for MSA.
- The Japan MSA research consortium (JAMSAC) was formed in 2003 to study MSA's natural history and pathogenesis.
Purpose:
- To understand the natural history of MSA for clinical trial design.
- To identify genes associated with MSA through advanced genome research.
- To develop more sensitive diagnostic criteria and biomarkers for earlier patient recruitment.
Summary:
- JAMSAC conducted a prospective study on MSA natural history using consensus criteria and UMSARS.
- Findings indicate MSA with predominant cerebellar ataxia (MSA-C) is more common in Japan than MSA with parkinsonism (MSA-P).
- Sensitive outcome measures beyond UMSARS are needed, alongside improved diagnostic criteria and biomarkers for efficient clinical trials.
Impact:
- Advances in genome research may identify MSA-related genes.
- Disease-modifying therapies for MSA are anticipated in the near future.
- Development of sensitive diagnostic criteria and biomarkers is crucial for effective MSA clinical trials.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...